-
1.发明公开METHOD FOR THE TREATMENT OF FLAVIVIRUS INFECTION, MOLECULES AND USES THEREOF 有权VERFAHREN ZUR BEHANDLUNG VON FLAVIVIRUS-INFEKTION，MOLEKÜLEUND IHRE VERWENDUNGEN
公开(公告)号：EP2022506A2
公开(公告)日：2009-02-11
申请号：EP07721810.5
申请日：2007-04-26
发明人： HUERTA GALINDO, Vivian , CHINEA SANTIAGO, Glay , FLEITAS SALAZAR, Noralvis , MARTÍN DUNN, Alejandro, Miguel , SARRÍA NÚÑEZ, Mónica , GUIROLA CRUZ, Osmany , TOLEDO MAYORA, Patricia, Gabriela , SÁNCHEZ PUENTE, Aniel , BESADA PÉREZ, Vladimir, Armando , REYES ACOSTA, Osvaldo , GARAY PÉREZ, Hilda, Elisa , CABRALES RICO, Ania , MUSACCHIO LASA, Alexis , PADRÓN PALOMARES, Gabriel, Ramón , GONZÁLEZ LÓPEZ, Luis, Javier
IPC分类号： A61K39/00
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C07K14/70596 , C07K14/8107 , C12N2770/24122 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396
摘要： The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.
摘要翻译： 本发明涉及一种基于干扰病毒包膜蛋白与细胞受体的直接相互作用或其通过载体蛋白与所述细胞受体的间接相互作用而阻断登革热病毒感染细胞的方法，以及相关的 使用; 其中所述细胞受体是α-2巨球蛋白受体，也称为低密度受体相关蛋白或CD91，所述载体蛋白是人α-2巨球蛋白。
-
2.发明授权
公开(公告)号：EP2022506B1
公开(公告)日：2017-10-11
申请号：EP07721810.5
申请日：2007-04-26
发明人： HUERTA GALINDO, Vivian , CHINEA SANTIAGO, Glay , FLEITAS SALAZAR, Noralvis , MARTÍN DUNN, Alejandro, Miguel , SARRÍA NÚÑEZ, Mónica , GUIROLA CRUZ, Osmany , TOLEDO MAYORA, Patricia, Gabriela , SÁNCHEZ PUENTE, Aniel , BESADA PÉREZ, Vladimir, Armando , REYES ACOSTA, Osvaldo , GARAY PÉREZ, Hilda, Elisa , CABRALES RICO, Ania , MUSACCHIO LASA, Alexis , PADRÓN PALOMARES, Gabriel, Ramón , GONZÁLEZ LÓPEZ, Luis, Javier
IPC分类号： A61K39/00
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C07K14/70596 , C07K14/8107 , C12N2770/24122 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396
摘要： The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.
-
3.发明公开
公开(公告)号：EP2085098A2
公开(公告)日：2009-08-05
申请号：EP07817384.6
申请日：2007-10-30
发明人： CHINEA SANTIAGO, Glay , HUERTA GALINDO, Vivian , MARTÍN DUNN, Alejandro Miguel , FLEITAS SALAZAR, Noralvis , GUIROLA CRUZ, Osmany , TOLEDO MAYORA, Patricia, Gabriela , SARRÍA NÚÑEZ, Mónica , MUSACCHIO LASA, Alexis , REYES ACOSTA, Osvaldo , GARAY PÉREZ, Hilda Elisa , CABRALES RICO, Ania
IPC分类号： A61K47/48
CPC分类号： A61K47/48315 , A61K38/00 , A61K47/645 , C07K14/005 , C07K2319/04 , C07K2319/10 , C12N2770/24022 , C12N2770/24122 , C12N2770/24222 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395
摘要： The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.
-
4.发明授权CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES 有权具有抗登革热病毒和其他黄病毒的抗病毒活性的化学化合物
公开(公告)号：EP2258356B1
公开(公告)日：2017-09-27
申请号：EP09714439.8
申请日：2009-02-27
发明人： MAZOLA REYES, Yuliet , CHINEA SANTIAGO, Glay , GUIROLA CRUZ, Osmany , VERA ALVAREZ, Roberto , HUERTA GALINDO, Vivian , FLEITAS SALAZAR, Noralvis , MUSACCHIO LASA, Alexis
IPC分类号： A61K31/428 , A61K31/495 , A61K31/00 , A61K31/496 , A61K31/4453 , A61K31/5375 , A61K31/5377 , A61K31/425 , A61K31/381 , A61K31/404 , A61K31/433 , A61K31/40 , A61K31/4192 , A61K31/34 , A61K31/505 , A61K31/55 , A61P31/14
CPC分类号： A61K31/16 , A61K31/18 , A61K31/381 , A61K31/41 , A61K31/426 , A61K31/428 , A61K31/44 , A61K31/495 , A61K31/4965 , A61K31/50 , A61K31/506 , A61K31/535 , A61K31/55 , A61K47/54 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395
摘要： Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions. The invention also comprises the use of such pharmaceutical compositions for prophylactic and/or therapeutic treatment of infection caused by all four serotypes of Dengue virus and other flaviviruses.
摘要翻译： 利用计算机获得的化学化合物制备药物组合物以减轻或抑制登革热病毒感染。 特别是通过干扰或调节与病毒进入宿主细胞相关的几个病毒复制周期阶段和成熟后代病毒体的组装。 本发明还包括这些药物组合物用于预防性和/或治疗性治疗由所有四种登革病毒血清型和其他黄热病病毒引起的感染的用途。
-
5.发明授权PEPTIDE CHIMERIC MOLECULES HAVING ANTIVIRAL PROPERTIES AGAINST VIRUSES OF THE FLAVIVIRIDAE FAMILY 有权CHIMÄREPEPTID-MOLEKÜLEMIT ANTIVIRALEN EIGENSCHAFTEN GEGEN VIREN DER FLAVIVIRIDAE-FAMILIE
公开(公告)号：EP2085098B1
公开(公告)日：2012-07-25
申请号：EP07817384.6
申请日：2007-10-30
发明人： CHINEA SANTIAGO, Glay , HUERTA GALINDO, Vivian , MARTÍN DUNN, Alejandro Miguel , FLEITAS SALAZAR, Noralvis , GUIROLA CRUZ, Osmany , TOLEDO MAYORA, Patricia, Gabriela , SARRÍA NÚÑEZ, Mónica , MUSACCHIO LASA, Alexis , REYES ACOSTA, Osvaldo , GARAY PÉREZ, Hilda Elisa , CABRALES RICO, Ania
IPC分类号： C07K19/00
CPC分类号： A61K47/48315 , A61K38/00 , A61K47/645 , C07K14/005 , C07K2319/04 , C07K2319/10 , C12N2770/24022 , C12N2770/24122 , C12N2770/24222 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395
摘要： The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.
摘要翻译： 本发明是相对于嵌合肽，其主要结构保持至少一个片段，其阻止来自黄病毒科的病毒的NS3蛋白酶的活化，它们还含有细胞穿透片段，并且它们能够抑制或减弱病毒 感染。 本发明还涉及含有这些嵌合肽用于预防和/或治疗由黄病毒科病毒引起的感染的药物化合物。
-
6.发明公开CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES 有权CHEMISCHE VERBINDUNGEN MIT ANTIVIRALER WIRKUNGGEGENÜBERDEM DENGUE-VIRUS UND ANDEREN FLAVIVIREN
公开(公告)号：EP2258356A2
公开(公告)日：2010-12-08
申请号：EP09714439.8
申请日：2009-02-27
发明人： MAZOLA REYES, Yuliet , CHINEA SANTIAGO, Glay , GUIROLA CRUZ, Osmany , VERA ALVAREZ, Roberto , HUERTA GALINDO, Vivian , FLEITAS SALAZAR, Noralvis , MUSACCHIO LASA, Alexis
IPC分类号： A61K31/00 , A61K31/496 , A61K31/4453 , A61K31/5375 , A61K31/5377 , A61K31/425 , A61K31/381 , A61K31/404 , A61K31/433 , A61K31/40 , A61K31/4192 , A61K31/34 , A61K31/505 , A61K31/55 , A61P31/14
CPC分类号： A61K31/16 , A61K31/18 , A61K31/381 , A61K31/41 , A61K31/426 , A61K31/428 , A61K31/44 , A61K31/495 , A61K31/4965 , A61K31/50 , A61K31/506 , A61K31/535 , A61K31/55 , A61K47/54 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395
摘要： Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions. The invention also comprises the use of such pharmaceutical compositions for prophylactic and/or therapeutic treatment of infection caused by all four serotypes of Dengue virus and other flaviviruses.
摘要翻译： 使用在硅胶中获得的化合物用于制备药物组合物以减轻或抑制登革热病毒感染。 特别是通过与病毒进入宿主细胞相关的几个阶段的病毒复制循环的干扰或调节以及成熟后代病毒粒子的组装。 本发明还包括使用这种药物组合物预防和/或治疗由登革热病毒和其他黄病毒的所有四种血清型引起的感染。
-
7.发明公开METHODS AND PROTEINS FOR THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF DENGUE VIRUS AND OTHER FLAVIVIRUSES 审中-公开方法和蛋白质用于预防和/或四种登革热病毒等多种黄病毒血清型的治疗
公开(公告)号：EP1958959A2
公开(公告)日：2008-08-20
申请号：EP06817996.9
申请日：2006-11-21
发明人： CHINEA SANTIAGO, Glay , HUERTA GALINDO, Vivian , MARTÍN DUNN, Alejandro, Miguel , GAVILONDO COWLEY, Jorge, Victor , FLEITAS SALAZAR, Noralvis , GUIROLA CRUZ, Osmany , GIL VALDÉS, Jeovanis , ZULUETA MORALES, Aída , HERMIDA CRUZ, Lisset , AYALA AVILA, Marta , GONZÁLEZ ROCHE, Diamilé , PAEZ MEIRELES, Rolando , TOLEDO MAYORA, Patricia, Gabriela , SARRÍA NÚÑEZ, Mónica , MUSACCHIO LASA, Alexis , MAZOLA REYES, Yuliet
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K2039/55566 , C07K2319/02 , C07K2319/21 , C12N2770/24022 , C12N2770/24122 , C12N2770/24134 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396
摘要： The present invention is related to the field of the pharmaceutical industry, and describes a conserved area on the surface of the E protein that can be used for the development of wide-spectrum antiviral molecules to be employed in the prophylaxis and/or treatment of infections due to Dengue Virus serotypes 1-4 and other flaviviruses. The invention also covers chimeric proteins to be used as vaccines or as a prophylactic or therapeutic treatment against the four serotypes of Dengue Virus and other flaviviruses.
摘要翻译： 本发明涉及制药工业领域，并且描述了E蛋白的表面上的一个保守的区域也可用于广谱抗病毒分子的发展感染的预防和/或治疗要采用 由于登革热病毒血清型1-4和其他黄病毒。 因此，本发明涵盖了嵌合蛋白用作疫苗或作为针对登革病毒和其他黄病毒的四种血清型的预防或治疗性治疗。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.02 秒)
